A study of 818 patients with vasospastic angina (VSA) categorized according to tertiles of serum uric acid (sUA) level aimed to evaluate the association between sUA and major adverse cardiac effects (MACEs). 1 At a rate of 17.1%, patients in the second tertile group (sUA = 4.9-5.9 mg/dL) showed a significantly lower risk of MACE compared to the 24.6% patients in the first tertile group (sUA ≤ 4.8 mg/dL) (hazard ratio [HR], 1.52; 95% confidence interval [CI], 1.02-2.26; P = 0.040). Compared to the 22.5% rate in the third group (sUA ≥ 6.0 mg/ dL), the second group showed, in the authors' words, a "tendency," though non-significant, of lower risk (HR, 1.44; 95% CI, 0.98-2.13; P = 0.067).
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By foregoing the continuous mg/dL scale of sUA level for the discrete tertile-based categorization, the association evaluated is no longer with sUA level (mg/dL) but with tertile group membership (I-III). Per Table 2 , a simple 3 × 2 contingency analysis of group membership by MACE (non-)occurrence yields a statistically non-significant χ 2 = 4.91 (P = 0.086), indicating that group membership and MACE (non-)occurrence are independent events. Validity-wise, do the categorization cut-off values correspond to indications from animal or human studies? In other words, is there evidence that 4.9 and 6.0 mg/dL are physiologically and clinically defensible marks; not in general, but in relation to MACE? With continuous sUA data, a logistic model of MACE as a function of sUA level, controlling for potential confounders, would have answered the question as to whether sUA level is a risk factor for MACE.
With the contingency analysis telling us that, overall, the three groups did not differ in MACE rates, the Kaplan-Meier curves and associate log-rank tests ( Fig. 2A-C) compare the pace at which (the statistically equivalent) MACE events occurred in each group. Fig. 2A indicates that patients in group II who experienced a MACE did so relatively later than patients in groups I and III. Fig. 2B conveys that this was more pronounced when focusing on the pure VSA patients but not, as Fig. 2C reports, on mixed-angina patients. Together, the three figures confirm that, in the end, all three groups are likely to end with statistically similar probabilities of experiencing MACE.
